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ABSTRACT
Objective  To assess the efﬁ  cacy and safety of abatacept 
in biological-naive patients with rheumatoid arthritis and 
an inadequate response to methotrexate treated in the 
long-term extension (LTE) of the ATTEST trial.
Methods  Patients randomly assigned to abatacept, 
placebo or inﬂ  iximab completing the 1-year double-blind 
period were eligible to receive abatacept ~10 mg/kg 
in the open-label LTE. Efﬁ  cacy to year 2 is presented for 
patients randomly assigned to abatacept or inﬂ  iximab 
who switched to open-label abatacept. Safety data are 
presented for all patients entering LTE regardless of 
double-blind treatment.
Results  Of 431 patients randomly assigned, 79.8% 
remained on abatacept at year 2. At years 1 and 2, 
19.7% and 26.1% of abatacept and 13.3% and 28.6% 
of inﬂ  iximab-to-abatacept patients achieved disease 
activity score 28-deﬁ  ned remission (<2.6). Safety 
with abatacept during the cumulative study period was 
consistent with the double-blind experience, with no 
increase in adverse event incidence following the switch 
to abatacept.
Conclusion  In methotrexate-inadequate responders, 
abatacept efﬁ  cacy was maintained over 2 years. For 
inﬂ  iximab-to-abatacept patients, efﬁ  cacy improvements 
were seen in year 2 after patients switched to abatacept. 
Switching directly from inﬂ  iximab to abatacept was 
well tolerated. These data demonstrate that abatacept 
provides sustained responses and consistent safety, 
suggesting that switching from inﬂ  iximab to abatacept is 
a viable treatment option.
Randomised clinical trials have assessed the efﬁ  -
cacy and safety of switching to abatacept (T-cell 
costimulation modulator), rituximab (B-cell deplet-
ing therapy) or tocilizumab (interleukin-6 inhibitor) 
after failure of anti-tumour necrosis factor (TNF) 
agents.1–5 However, there is a paucity of informa-
tion on the efﬁ  cacy and safety of switching from 
one mechanism of action to another in patients 
who have not failed previous anti-TNF therapy due 
to lack of efﬁ  cacy.
The Abatacept or inﬂ  iximab versus placebo, a 
Trial for Tolerability, Efﬁ  cacy and Safety in Treating 
rheumatoid arthritis (ATTEST) trial provided a 
unique opportunity to assess clinical efﬁ  cacy and 
safety outcomes in biological-naive patients who 
switched from an anti-TNF to abatacept, regardless 
of earlier treatment response − that is including both 
patients in high, moderate or low disease states, or 
with American College of Rheumatology (ACR) 
20, 50 or 70 responses, at the end of 12 months of 
inﬂ  iximab treatment. Such observations could help 
inform clinical decision-making following treat-
ment withdrawal for either safety or efﬁ  cacy-re-
lated reasons. In the 1-year double-blind period of 
ATTEST, although a greater proportion of patients 
achieved ACR20 at month 1 with inﬂ  iximab ver-
sus abatacept, by month 3 responses were similar. 
Both biological agents demonstrated comparable 
efﬁ  cacy compared with placebo at 6 months; fur-
ther improvements were observed with abatacept 
over 1 year.6 There were numerically fewer serious 
adverse events (SAE) and serious infections with 
abatacept versus inﬂ  iximab over 1 year.
Here, we report the efﬁ   cacy and safety from 
the 1-year open-label long-term extension (LTE) of 
ATTEST, in which all patients received open-label 
abatacept, regardless of double-blind treatment or 
treatment response.
METHODS
Patients and study design
Patients had an inadequate response to methotrex-
ate with active disease at randomisation, as previ-
ously described.6 Patients were randomly assigned 
(3:3:2), using a double-dummy regimen,6 to receive 
intravenous abatacept (~10 mg/kg based on 
weight range), inﬂ  iximab (ﬁ  xed-dose 3 mg/kg) or 
placebo, plus background methotrexate. Placebo-
treated patients were switched to abatacept at 
month 6. At month 12, patients from each treat-
ment group could enter the open-label LTE, during 
which they received abatacept every 28 days. For 
patients switching from inﬂ  iximab, there was no 
washout period before the ﬁ  rst abatacept infusion. 
Patients were monitored monthly, at each study 
visit. During the open-label LTE, physicians could 
add a non-biological disease-modifying antirheu-
matic drug and adjust corticosteroid and metho-
trexate doses. The active-controlled ATTEST trial, 
requested by the authorities, was initially powered 
to detect reductions in disease activity with abata-
cept versus placebo over 6 months. Although not 
powered for, comparisons in safety and efﬁ  cacy 
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RESULTS
Patient disposition, baseline demographics and clinical 
characteristics
Of the 431 patients originally randomly assigned to abatacept 
(n=156), inﬂ   iximab (n=165) or placebo (n=110), 344 (79.8%) 
patients remained on abatacept at year 2. Detailed patient dis-
position data are provided in supplementary ﬁ  gure 1 (available 
online only). Patient demographics and baseline clinical charac-
teristics for patients who entered the LTE were consistent with 
those for the original randomly assigned population,6 and were 
comparable between original groups (supplementary table A, 
available online only).
Concomitant medications
During the 1-year open-label LTE, 98.5% of all patients (both 
original abatacept and inﬂ  iximab arms) received concomitant 
methotrexate. Other than methotrexate, concomitant non-bi-
ological disease-modifying antirheumatic drugs administered 
during the LTE included azathioprine (for original abatacept and 
inﬂ  iximab arms, respectively; 0.8% vs 3.7%), hydroxychloro-
quine/chloroquine (1.5% vs 2.2%), leﬂ  unomide (2.3% vs 3.7%) 
and sulfasalazine (4.5% vs 4.4%).
Clinical efﬁ  cacy
The proportions of patients achieving DAS28-deﬁ  ned LDAS 
and remission, and those achieving SDAI-deﬁ  ned low disease 
activity and remission are shown in ﬁ  gure 1A,B. Rates of LDAS 
and remission, according to both DAS28 and SDAI, increased 
numerically from year 1 to year 2 in the original abatacept 
group; for patients originally randomly assigned to inﬂ  iximab, 
rates increased following the switch to abatacept. ACR 50 and 
70 responses, EULAR responses, reductions from baseline in 
DAS28 (ESR) and HAQ-DI scores are shown in the supplemen-
tary material available online only.
between abatacept and inﬂ  iximab were prespeciﬁ  ed. The pri-
mary objective of the open-label LTE, however, was to evaluate 
safety in patients who remained on treatment.
Efﬁ  cacy assessments
Clinical efﬁ  cacy was a secondary objective of this study, and 
results are presented at 6-month intervals during the open-label 
LTE for patients originally randomly assigned to either abata-
cept or inﬂ  iximab, who received at least one abatacept infusion 
in the LTE; data for patients randomly assigned to placebo are 
not shown. Disease activity was assessed by the disease activity 
score in 28 joints (DAS28; erythrocyte sedimentation rate (ESR), 
low disease activity state (LDAS) ≤3.2; remission <2.6),7 and by 
the simpliﬁ  ed disease activity index (SDAI; low disease activity 
≤11.0; remission ≤3.3). ACR8 and EULAR responses9 and health 
assessment questionnaire-disability index (HAQ-DI)10 scores 
were recorded, and are provided in the supplementary informa-
tion available online only. Results are shown for patients with 
data available at the visit of interest (as-  observed analysis).
Patient-level, post-hoc analyses of shifts in ACR responses 
and DAS28 status from year 1 to year 2 were performed in 
patients who originally received inﬂ  iximab and then switched 
to abatacept. Mutually exclusive categories were used to deﬁ  ne 
ACR responses and DAS28 status, detailed in table 1.
Safety assessments
Adverse events were monitored monthly at each study visit. The 
safety of abatacept during the cumulative period (1-year double-
blind plus 1-year LTE) is presented as incidence rates (IR) for 
patients who received at least one infusion of abatacept, regard-
less of initial randomisation. In addition, events that occurred 
during open-label abatacept treatment in patients originally ran-
domly assigned to inﬂ  iximab are shown alongside events that 
occurred in the double-blind period with abatacept or inﬂ  iximab 
for comparison.
Table 1  Post-hoc analyses of shifts in ACR responses and DAS28 (ESR) states between year 1 and 
year  2, following switch from inﬂ  iximab to abatacept
ACR response* at year 1 Shifts in ACR response* by year 2, n (%)
Total, n (%)
No 
response
ACR20 
(not ACR50/70)
ACR50 
(not ACR70) ACR70
No response 39 (30.7) 10 (25.6) 11 (28.2) 13 (33.3) 5 (12.8)
ACR 20 
(but not ACR50/70) 32 (25.2) 7 (21.9) 5 (15.6)   9 (28.1) 11 (34.4)
ACR 50 
(but not ACR70) 24 (18.9) 3 (12.5) 1 (4.2)   8 (33.3) 12 (50.0)
ACR 70 32 (25.2) 0 0   3 (9.4) 29 (90.6)
DAS28 (ESR) status* at year 1 Shifts in DAS28 (ESR) status* by year 2, n (%)
Total, n (%)
HDAS 
(DAS28 >5.1)
MDAS 
(DAS28 >3.2–5.1)
LDAS 
(DAS28 2.6–3.2)
Remission 
(DAS28 <2.6)
HDAS 
(DAS28 >5.1) 39 (31.2) 8 (20.5) 25 (64.1) 2 (5.1) 4 (10.3)
MDAS 
(DAS28 >3.2–5.1) 56 (44.8) 4 (7.1) 25 (44.6) 15 (26.8) 12 (21.4)
LDAS 
(DAS28 2.6–3.2) 12 (9.6) 1 (8.3) 4 (33.3) 1 (8.3) 6 (50.0)
Remission 
(DAS28 <2.6) 18 (14.4) 0 1 (5.6) 3 (16.7) 14 (77.8)
*ACR response and DAS28 status categories are discrete.
ACR, American College of Rheumatology; DAS28, disease activity score in 28 joints; ESR, erythrocyte sedimentation rate; HDAS, 
high disease activity state; LDAS, low disease activity state; MDAS, moderate disease activity state.
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Figure 1  Data are for patients originally assigned to abatacept or inﬂ  iximab and switched to abatacept at year 1. Original placebo group is not 
shown. (A). Percentage (95% CI) of patients in DAS28 (ESR) LDAS and remission. At year 1, 37.0 (95% CI: 28.6 to 45.4) vs 23.0% (15.9 to 30.1) of 
abatacept- versus inﬂ  iximab-treated patients, respectively, achieved LDAS, and 19.7 (12.8 to 26.6) versus 13.3% (7.6 to 19.1) achieved remission. 
At year 2, 41.7 (95% CI: 32.7 to 50.8) versus 45.2% (36.5 to 53.9) of original abatacept versus inﬂ  iximab-to-abatacept switch patients, respectively, 
achieved LDAS, and 26.1 (18.1 to 34.1) versus 28.6% (20.7 to 36.5) achieved remission. (B). Percentage (95% CI) of patients in SDAI LDA and 
remission. At year 1, 56.2 (95% CI: 47.6 to 64.7) versus 38.5% (30.3 to 46.7) of abatacept- vs inﬂ  iximab-treated patients, respectively, achieved 
LDA, and 13.1 (7.3 to 18.9) versus 11.9% (6.4 to 17.3) achieved remission. At year 2, 63.5 (95% CI: 54.7 to 72.3) versus 65.1% (56.8 to 73.4) of original 
abatacept vs inﬂ  iximab-to-abatacept switch patients, respectively, achieved LDA, and 21.7 (14.2 to 29.3) versus 24.6% (17.1 to 32.1) achieved remission.
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The IR of adverse events did not increase during abatacept 
treatment in the LTE for patients treated with inﬂ  iximab and 
switched to abatacept at year 1 (291.4 (242.0, 347.9)), compared 
with that for patients treated with inﬂ  iximab during the double-
blind period (448.6 (380.6, 525.3); table 2). SAE and infections 
for original inﬂ  iximab patients were reported at IR of 16.5 (10.1, 
25.4) and 96.9 (76.9, 120.4) in the LTE versus 21.1 (14.2, 30.1) and 
134.1 (110.6, 161.1) in the double-blind period; serious infections 
and opportunistic infections at IR of 1.5 (0.2, 5.6) and 0.0 (0.0, 
0.0) versus 9.2 (5.0, 15.5) and 2.6 (0.7, 6.6); and acute infusional 
reactions at IR of 8.9 (4.4, 15.9) versus 32.3 (23.3, 43.6).
DISCUSSION
The ATTEST trial provided an opportunity to assess the efﬁ  cacy 
of abatacept over 2 years while concurrently evaluating patients 
who were switched to abatacept after initial treatment with 
inﬂ  iximab. In the original abatacept group, improvements in 
disease activity achieved by the end of the double-blind period 
were maintained with continued abatacept treatment through 
the LTE. For patients switched from inﬂ  iximab to abatacept at 
year 1, clinical efﬁ  cacy beneﬁ  ts were maintained or increased 
following the switch. Observed efﬁ  cacy beneﬁ  ts are supported 
by good retention rates, consistent with previous abatacept 
experience in this population.11 12
The majority of individual patients who switched to abata-
cept improved or maintained their treatment response or dis-
ease activity level at year 2, regardless of the initial response 
to inﬂ  iximab. Many patients who had not achieved a response, 
or were still in high/moderate disease activity after 1 year of 
inﬂ  iximab, achieved a response or improved their disease activ-
ity state with abatacept. In addition, the majority of patients 
achieving ACR 70 responses or DAS28 remission with inﬂ  ix-
imab maintained this response or state when switched. These 
data reassure the clinician that a patient treated with inﬂ  iximab, 
who has experienced a good clinical response, may expect to 
have a continued good response with consistent safety if they 
Patient-level clinical efﬁ  cacy analyses
After 1 year of inﬂ  iximab treatment, 30.7% of patients were 
ACR 20 non-responders, and 25.2%, 18.9% and 25.2% achieved 
ACR 20, 50 and 70 responses, respectively, with 31.2%, 44.8%, 
9.6% and 14.4% of patients in high disease activity state, moder-
ate disease activity state (MDAS), LDAS and remission, respec-
tively. Table 1 shows the shifts in ACR responses and DAS28 
states for these patients from years 1 to 2.
Safety
Abatacept was generally well tolerated over the cumulative 
2-year study period (table 2). Osteoarthritis (ﬁ  ve patients) was 
the only SAE reported in 1% or more of patients, other than 
worsening of rheumatoid arthritis. Two deaths were reported in 
the open-label period (respiratory failure and accidental).
The most common infections (≥10% of patients) were 
nasopharyngitis, urinary tract infection, upper respiratory tract 
infection, inﬂ  uenza and pharyngitis; and for serious infections 
were pneumonia and urinary tract infection (three patients 
each). There was a single report of latent tuberculosis during 
the LTE in a patient originally randomly assigned to inﬂ  iximab, 
considered severe. The patient had a negative chest x-ray and 
puriﬁ  ed protein derivative (PPD) test at study entry, and a posi-
tive PPD test and chronic bronchitis and basal ﬁ  brosis on x-ray 
at month 6 of the LTE; the patient did not discontinue and the 
event resolved after approximately 1 year.
Two malignancies were reported in the LTE, including basal cell 
carcinoma in a patient originally randomly assigned to abatacept, 
which was classiﬁ  ed as serious and possibly related to treatment.
All autoimmune events were mild or moderate in intensity; 
psoriasis was the most frequent event and was reported in three 
patients.
Acute infusional adverse events occurred in 11 patients origi-
nally randomly assigned to inﬂ  iximab after they switched to 
abatacept. The most common events (≥1% of patients) were 
headache, dizziness and nausea.
Table 2 Adverse  events
Incidence rate (95% CI)
Double-blind period Cumulative 2-year 
study period†
Abatacept, n=399 Abatacept*, n=156 Inﬂ  iximab*, n=165
Mean (range) months of exposure 11.7 (2.4 – 13.3) 11.6 (1.9 – 13.1) 17.2 (1.9 – 26.5)
Deaths 0.7 (0.0 to 3.7) 1.3 (0.2 to 4.6) 0.7 (0.2 to 1.8)
AE 326.0 (274.1 to 384.9) 448.6 (380.6 to 525.3) 257.5 (231.8 to 285.3)
SAE 11.8 (6.9 to 18.9) 21.1 (14.2 to 30.1) 15.2 (12.0 to 19.0)
Infections 99.8 (80.4 to 122.4) 134.1 (110.6 to 161.1) 86.2 (76.2 to 97.3)
Serious infectious events 2.0 (0.4 to 5.9) 9.2 (5.0 to 15.5) 1.6 (0.7 to 3.1)
Opportunistic infections 0 2.6 (0.7 to 6.6) 0.2 (0.0 to 1.0)
Neoplasms‡ 2.7 (0.7 to 6.9) 3.2 (1.0 to 7.5) 2.7 (1.5 to 4.5)
Malignant neoplasms 0.7 (0.0 to 3.7) 1.3 (0.2 to 4.6) 0.4 (0.0 to 1.3)
Autoimmune symptoms or events 1.3 (0.2 to 4.8) 0.6 (0.0 to 3.6) 1.4 (0.6 to 2.8)
Acute infusional AE 7.7 (3.8 to 13.8) 32.3 (23.3 to 43.6) 6.4 (4.5 to 9.0)
*Represents original randomisation group and events experienced in the double-blind period (updated database lock relative to 
previously published double-blind ﬁ  ndings).6
†Patients who received at least one infusion of abatacept in the cumulative study period (double-blind or long-term extension), 
regardless of original randomisation group.
‡Benign, malignant and unspeciﬁ  ed.
Incidence rates (IR) are calculated as the number of patients with the event of interest, divided by total exposure 
(patient-years) during the speciﬁ  ed treatment period, multiplied by 100 to provide incidence/100 patient-years of exposure. 
A patient’s contribution to exposure ended at the time of ﬁ  rst occurrence of the speciﬁ  c AE.
AE, adverse event; SAE, serious adverse event.
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are switched to abatacept; an important clinical consideration if 
patients are switched because of safety concerns.
Abatacept was generally safe and well tolerated during this 
study. Transitioning patients directly from inﬂ  iximab to abata-
cept without a washout period did not result in higher overall 
frequencies of SAE or infections after switching medication, rel-
ative to previous double-blind inﬂ  iximab treatment over 1 year; 
in particular, incidence rates of serious and opportunistic infec-
tions were lower after patients switched to abatacept. These 
data support previously published ﬁ  ndings that demonstrated 
that switching directly from an anti-TNF to abatacept without a 
washout period was generally safe and well tolerated.4
The ﬁ  ndings presented here should be considered within cer-
tain limitations. Efﬁ  cacy data are based on as-observed analyses, 
which are vulnerable to dropouts; however, discontinuation rates 
were relatively low and, therefore, the ﬁ  ndings probably provide 
an accurate representation of the randomly assigned population. 
It should be noted that the patient-level results reported here are 
post-hoc analyses, and caution should be used with such data. 
During the 1-year double-blind period, the inﬂ  iximab dose could 
not be increased beyond 3 mg/kg, the recommended dosing 
regimen at the time of trial design. In the current clinical setting, 
many physicians use approved higher doses, although there has 
been extensive debate over the efﬁ  cacy beneﬁ  ts of such dose 
escalation13–15 and reports of an increased incidence of infec-
tions with higher doses.16 However, the objective of the current 
study was to assess safety and efﬁ  cacy in patients who switch to 
abatacept, regardless of treatment response, and, thus, included 
patients responding to treatment with inﬂ  iximab. Therefore, the 
fact that dose escalation of inﬂ  iximab was not permitted in the 
double-blind period should not detract from these ﬁ  ndings.
The deﬁ   nition of an ‘inadequate response’ to therapy is 
changing, with clinical remission a clear therapeutic goal and 
LDAS an acceptable alternative in patients with long-standing, 
established disease.17 As such, patients and clinicians now have 
ever higher expectations of treatment. Physicians may consider 
switching patients who have achieved only moderate clinical 
improvements, such as an ACR 20 response or MDAS. The ﬁ  nd-
ings presented here suggest that abatacept is a viable treatment 
option for such patients.
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